<p>Compass Therapeutics, Inc. (NASDAQ:CMPX - 获取免费报告) 的股价在周一的午盘交易中创下 52 周新低。该公司的股价最低跌至 1.61 美元，最后交易价格为 1.79 美元，成交量为 157953676 股。该股票此前收盘价为 5.03 美元。</p>
<p>获取 <strong>Compass Therapeutics</strong> 的提醒：</p>
<h2>华尔街分析师预测增长</h2>
<ul>
<li>分析师仍看好前三家高动量公司</li>
</ul>
<p>多家股票研究分析师最近对该公司发布了报告。HC Wainwright 在周一的研究报告中重申了 “买入” 评级，并对 Compass Therapeutics 的股票设定了 24.00 美元的目标价。Wall Street Zen 在周六的研究报告中将 Compass Therapeutics 的评级从 “持有” 下调至 “卖出”。Guggenheim 在 3 月 24 日的研究报告中重申了 “买入” 评级，并对 Compass Therapeutics 的股票设定了 12.00 美元的目标价。William Blair 在 3 月 5 日的研究报告中重申了对 Compass Therapeutics 股票的 “跑赢大盘” 评级。最后，Craig Hallum 在 2 月 13 日的报告中开始覆盖 Compass Therapeutics。他们设定了 “买入” 评级和 15.00 美元的目标价。一位投资分析师对该股票给予了强烈买入评级，十二位分析师给予了买入评级，一位分析师对该公司给予了卖出评级。根据 MarketBeat.com 的数据，该股票目前的平均评级为 “适度买入”，平均目标价为 14.20 美元。</p>
<p><strong>阅读我们关于 CMPX 的最新报告</strong></p>
<h2>Compass Therapeutics 股票下跌 64.4%</h2>
<p>该公司的市值为 3.2236 亿美元，市盈率为-4.16，贝塔值为 1.49。该股票的 50 日移动平均线为 5.46 美元，200 日移动平均线为 5.28 美元。</p>
<p>Compass Therapeutics (NASDAQ:CMPX - 获取免费报告) 最近在 3 月 5 日发布了其财报。该公司报告每股收益（EPS）为-0.09 美元，超出分析师的共识预期（-0.10 美元）0.01 美元。股票分析师预测 Compass Therapeutics, Inc. 在当前财政年度将发布-0.41 的每股收益。</p>
<h2>机构资金流入和流出</h2>
<p>对冲基金和其他机构投资者最近买卖了该公司的股票。Flagship Harbor Advisors LLC 在第四季度购买了 Compass Therapeutics 的新股份，价值约 32,000 美元。Russell Investments Group Ltd. 在第三季度将其在 Compass Therapeutics 的持股增加了 3933.7%。Russell Investments Group Ltd. 现在拥有该公司 7,785 股股票，价值 27,000 美元，此前在此期间又购买了 7,592 股。Apollon Wealth Management LLC 在第三季度购买了 Compass Therapeutics 的新头寸，价值 35,000 美元。Xponance LLC 在第四季度购买了 Compass Therapeutics 的新头寸，价值 55,000 美元。最后，CIBC Bancorp USA Inc. 在第三季度购买了价值约 37,000 美元的 Compass Therapeutics 新股份。机构投资者持有该公司 68.43% 的股票。</p>
<h2>Compass Therapeutics 公司简介</h2>
<p>(获取免费报告)</p>
<p>Compass Therapeutics, Inc 是一家临床阶段的生物技术公司，致力于新型免疫肿瘤疗法的发现和开发。公司总部位于马萨诸塞州剑桥，专注于工程化单克隆抗体候选药物，旨在增强 T 细胞介导的抗肿瘤反应。Compass 利用专有抗体平台识别和优化调节免疫检查点通路和肿瘤微环境的生物制剂。</p>
<p>该公司的主要项目包括 CTX-471，一种双特异性抗体，靶向 PD-1 和 PD-L1 检查点，以及 DSP107，一种 CD47-SIRPα 通路调节剂，旨在破坏癌细胞上的 “别吃我” 信号。</p>
<h2>另见</h2>
<ul>
<li>五只我们更看好的股票，胜过 Compass Therapeutics</li>
</ul>
<p><em>此即时新闻提醒由叙事科学技术和来自 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 Compass Therapeutics 吗？</h2>
<p>在你考虑 Compass Therapeutics 之前，你会想听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前立即购买……而 Compass Therapeutics 并不在名单上。</p>
<p>虽然 Compass Therapeutics 目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

CMPX

<p>Compass Therapeutics（纳斯达克代码：CMPX）股价创下 52 周新低，报 1.61 美元，收盘价为 1.79 美元，交易量显著。分析师的评级意见不一：HC Wainwright 维持 “买入” 评级，目标价为 24 美元，而 Wall Street Zen 则下调至 “卖出”。该股票市值为 3.2236 亿美元，市盈率为-4.16。机构投资者持有 68.43% 的股份。该公司专注于免疫肿瘤治疗，报告的每股收益为（0.09 美元），略高于预期。分析师预测评级为适度买入，平均目标价为 14.20 美元</p>

<p>Compass Therapeutics, Inc. (NASDAQ:CMPX - Get Free Report)'s share price hit a new 52-week low during mid-day trading on Monday . The company traded as low as $1.61 and last traded at $1.79, with a volume of 157953676 shares trading hands. The stock had previously closed at $5.03.</p>
<div class="lb-trans"><p>Compass Therapeutics, Inc. (NASDAQ:CMPX - 获取免费报告) 的股价在周一的午盘交易中创下 52 周新低。该公司的股价最低跌至 1.61 美元，最后交易价格为 1.79 美元，成交量为 157953676 股。该股票此前收盘价为 5.03 美元。</p>
</div><p>Get <strong>Compass Therapeutics</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Compass Therapeutics</strong> 的提醒：</p>
</div><h2>Wall Street Analysts Forecast Growth</h2>
<div class="lb-trans"><h2>华尔街分析师预测增长</h2>
</div><ul>
<li>Top 3 High-Momentum Companies Analysts Are Still Bullish On</li>
</ul>
<div class="lb-trans"><ul>
<li>分析师仍看好前三家高动量公司</li>
</ul>
</div><p>A number of equities research analysts recently issued reports on the company. HC Wainwright reissued a &#34;buy&#34; rating and issued a $24.00 target price on shares of Compass Therapeutics in a research report on Monday. Wall Street Zen downgraded Compass Therapeutics from a &#34;hold&#34; rating to a &#34;sell&#34; rating in a research note on Saturday. Guggenheim restated a &#34;buy&#34; rating and issued a $12.00 price target on shares of Compass Therapeutics in a research note on Tuesday, March 24th. William Blair reiterated an &#34;outperform&#34; rating on shares of Compass Therapeutics in a research report on Thursday, March 5th. Finally, Craig Hallum assumed coverage on Compass Therapeutics in a report on Friday, February 13th. They set a &#34;buy&#34; rating and a $15.00 price target for the company. One investment analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of &#34;Moderate Buy&#34; and an average price target of $14.20.</p>
<div class="lb-trans"><p>多家股票研究分析师最近对该公司发布了报告。HC Wainwright 在周一的研究报告中重申了 “买入” 评级，并对 Compass Therapeutics 的股票设定了 24.00 美元的目标价。Wall Street Zen 在周六的研究报告中将 Compass Therapeutics 的评级从 “持有” 下调至 “卖出”。Guggenheim 在 3 月 24 日的研究报告中重申了 “买入” 评级，并对 Compass Therapeutics 的股票设定了 12.00 美元的目标价。William Blair 在 3 月 5 日的研究报告中重申了对 Compass Therapeutics 股票的 “跑赢大盘” 评级。最后，Craig Hallum 在 2 月 13 日的报告中开始覆盖 Compass Therapeutics。他们设定了 “买入” 评级和 15.00 美元的目标价。一位投资分析师对该股票给予了强烈买入评级，十二位分析师给予了买入评级，一位分析师对该公司给予了卖出评级。根据 MarketBeat.com 的数据，该股票目前的平均评级为 “适度买入”，平均目标价为 14.20 美元。</p>
</div><p><strong>Read Our Latest Report on CMPX</strong></p>
<div class="lb-trans"><p><strong>阅读我们关于 CMPX 的最新报告</strong></p>
</div><h2>Compass Therapeutics Stock Down 64.4%</h2>
<div class="lb-trans"><h2>Compass Therapeutics 股票下跌 64.4%</h2>
</div><p>The company has a market capitalization of $322.36 million, a PE ratio of -4.16 and a beta of 1.49. The stock has a 50-day moving average of $5.46 and a 200 day moving average of $5.28.</p>
<div class="lb-trans"><p>该公司的市值为 3.2236 亿美元，市盈率为-4.16，贝塔值为 1.49。该股票的 50 日移动平均线为 5.46 美元，200 日移动平均线为 5.28 美元。</p>
</div><p>Compass Therapeutics (NASDAQ:CMPX - Get Free Report) last released its earnings results on Thursday, March 5th. The company reported ($0.09) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.10) by $0.01. Equities analysts forecast that Compass Therapeutics, Inc. will post -0.41 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>Compass Therapeutics (NASDAQ:CMPX - 获取免费报告) 最近在 3 月 5 日发布了其财报。该公司报告每股收益（EPS）为-0.09 美元，超出分析师的共识预期（-0.10 美元）0.01 美元。股票分析师预测 Compass Therapeutics, Inc. 在当前财政年度将发布-0.41 的每股收益。</p>
</div><h2>Institutional Inflows and Outflows</h2>
<div class="lb-trans"><h2>机构资金流入和流出</h2>
</div><p>Hedge funds and other institutional investors have recently bought and sold shares of the business. Flagship Harbor Advisors LLC purchased a new stake in shares of Compass Therapeutics in the 4th quarter worth approximately $32,000. Russell Investments Group Ltd. raised its holdings in Compass Therapeutics by 3,933.7% in the 3rd quarter. Russell Investments Group Ltd. now owns 7,785 shares of the company's stock worth $27,000 after purchasing an additional 7,592 shares during the period. Apollon Wealth Management LLC bought a new position in Compass Therapeutics in the 3rd quarter worth $35,000. Xponance LLC bought a new position in Compass Therapeutics in the 4th quarter worth $55,000. Finally, CIBC Bancorp USA Inc. bought a new stake in Compass Therapeutics during the third quarter valued at about $37,000. Institutional investors own 68.43% of the company's stock.</p>
<div class="lb-trans"><p>对冲基金和其他机构投资者最近买卖了该公司的股票。Flagship Harbor Advisors LLC 在第四季度购买了 Compass Therapeutics 的新股份，价值约 32,000 美元。Russell Investments Group Ltd. 在第三季度将其在 Compass Therapeutics 的持股增加了 3933.7%。Russell Investments Group Ltd. 现在拥有该公司 7,785 股股票，价值 27,000 美元，此前在此期间又购买了 7,592 股。Apollon Wealth Management LLC 在第三季度购买了 Compass Therapeutics 的新头寸，价值 35,000 美元。Xponance LLC 在第四季度购买了 Compass Therapeutics 的新头寸，价值 55,000 美元。最后，CIBC Bancorp USA Inc. 在第三季度购买了价值约 37,000 美元的 Compass Therapeutics 新股份。机构投资者持有该公司 68.43% 的股票。</p>
</div><h2>Compass Therapeutics Company Profile</h2>
<div class="lb-trans"><h2>Compass Therapeutics 公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>(获取免费报告)</p>
</div><p>Compass Therapeutics, Inc is a clinical‐stage biotechnology company dedicated to the discovery and development of novel immuno‐oncology therapies. Headquartered in Cambridge, Massachusetts, the company focuses on engineering monoclonal antibody candidates designed to enhance T cell–mediated anti‐tumor responses. Compass leverages proprietary antibody platforms to identify and optimize biologics that modulate immune checkpoint pathways and the tumor microenvironment.</p>
<div class="lb-trans"><p>Compass Therapeutics, Inc 是一家临床阶段的生物技术公司，致力于新型免疫肿瘤疗法的发现和开发。公司总部位于马萨诸塞州剑桥，专注于工程化单克隆抗体候选药物，旨在增强 T 细胞介导的抗肿瘤反应。Compass 利用专有抗体平台识别和优化调节免疫检查点通路和肿瘤微环境的生物制剂。</p>
</div><p>The company's lead programs include CTX-471, a bispecific antibody targeting both PD-1 and PD-L1 checkpoints, and DSP107, a CD47‐SIRPα pathway modulator aimed at disrupting “don't eat me” signals on cancer cells.</p>
<div class="lb-trans"><p>该公司的主要项目包括 CTX-471，一种双特异性抗体，靶向 PD-1 和 PD-L1 检查点，以及 DSP107，一种 CD47-SIRPα 通路调节剂，旨在破坏癌细胞上的 “别吃我” 信号。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另见</h2>
</div><ul>
<li>Five stocks we like better than Compass Therapeutics</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票，胜过 Compass Therapeutics</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和来自 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Compass Therapeutics Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Compass Therapeutics 吗？</h2>
</div><p>Before you consider Compass Therapeutics, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑 Compass Therapeutics 之前，你会想听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Compass Therapeutics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前立即购买……而 Compass Therapeutics 并不在名单上。</p>
</div><p>While Compass Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Compass Therapeutics 目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Compass Therapeutics（纳斯达克股票代码：CMPX）创下 12 个月新低 - 接下来会如何发展？